FDA — authorised 1 May 2017
- Application: BLA761069
- Marketing authorisation holder: ASTRAZENECA UK LTD
- Status: supplemented
FDA authorised Imfinzi on 1 May 2017
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 1 May 2017; FDA has authorised it.
ASTRAZENECA UK LTD holds the US marketing authorisation.